Skip to content
Review Open access

Artificial intelligence and computational prediction models for risk stratification, treatment response, and outcomes in colorectal cancer: a narrative review

Sep 2026 · Frontiers in Oncology · Vol 16 · 0 citations · 135 references
Medicine

TL;DR

A decision-centred synthesis indicates that CRC AI is most mature as site-specific and task-specific reader assistance or triage rather than autonomous decision-making.

Abstract

Purpose To critically evaluate, within a decision-centred framework, the clinical readiness of artificial-intelligence (AI) and computational prediction models used for risk stratification, treatment-response assessment, and outcome prediction in colorectal cancer (CRC), while distinguishing tumour site, intended clinical decision, assessment time point, and validation level, and identifying the gap between predictive performance and clinical impact. Methods PubMed/MEDLINE and Web of Science were searched for English-language studies published from January 2010 through 31 May 2026; ScienceDirect, Google Scholar, reference lists, and forward citation tracking were used as supplementary sources. Two reviewers independently screened studies and extracted design, endpoint, data modality, unit of analysis, validation, calibration, decision analysis, workflow evaluation, accessibility, and clinical-impact evidence. Study-level methodological features were assessed separately from task-level translational readiness. Results Comparatively stronger evidence was found for computer-aided endoscopic assessment of invasion depth, MRI-based lymph-node prediction in rectal cancer, H&E whole-slide-image pre-screening for MSI/MMR status, and selected externally tested models for pathological complete response. Evidence remained early-stage for CT-based nodal staging in colon cancer, tumour mutational burden prediction, neoadjuvant immunotherapy-response prediction, synchronous distant-metastasis assessment, recurrence, survival, and most perioperative-risk models. Prospective validation was uncommon and was not equivalent to demonstration of clinical benefit. Conclusion A decision-centred synthesis indicates that CRC AI is most mature as site-specific and task-specific reader assistance or triage rather than autonomous decision-making. Clinical translation requires representative external validation, calibration, predefined action thresholds, model availability, workflow testing, safety monitoring, and prospective evidence that model-guided care improves decisions or outcomes.

Read PDF

Similar papers

Review Open access Oct 2026

Artificial Intelligence in Gastric Cancer: Diagnostic, Prognostic, and Predictive Developments, Evidence Maturity, and Translational Challenges

ABSTRACT Background Gastric cancer (GC) remains a major global health burden characterized by substantial heterogeneity in diagnosis, prognosis, and treatment response. Artificial intelligence (AI), including machine learning (ML) and deep learning (DL), has been increasingly investigated for the analysis of endoscopic...

Chong Chen, Wei-Song Xu, Tong-Le Wu et al. · 0 citations
Review Nov 2026

Artificial Intelligence Models to Predict Recurrence in Patients with Differentiated Thyroid Cancer: A PROBAST + AI Systematic Review of Clinical Applicability.

BACKGROUND Differentiated thyroid cancer (DTC) generally carries an excellent prognosis, yet recurrence occurs in up to 8-9% of patients. Artificial intelligence (AI) models are increasingly proposed to predict DTC recurrence; however, their methodological quality and clinical readiness are poorly defined. We conducted...

P. Solis-Pazmino, Alison Fernanda Samaniego, L. Golbert et al. · 0 citations
Review Open access Oct 2026

Prognostic Evidence for Artificial Intelligence-Derived PET Tumour-Burden Biomarkers in Cancer: A Systematic Review

Background/Objectives: Artificial intelligence (AI) can automate tumour-burden measurement on positron emission tomography (PET), including metabolic tumour volume (MTV) and total metabolic tumour volume (TMTV). This review evaluated prognostic evidence for AI-derived PET tumour-burden biomarkers, particularly comparis...

S. Byun, Yunhwi Hwang, H. Kim et al. · 0 citations
Review Open access Oct 2026

Artificial intelligence in pancreatic cancer surgery: evidence maturity, boundaries, and clinical translation

Pancreatic cancer surgery requires decisions about resectability, treatment sequencing, operative planning, complications, and prognosis. We mapped artificial intelligence (AI) studies to five surgical decision domains and evaluated study design, validation, performance, decision utility, workflow fit, and evidence lim...

Zhi-Ke Li, Gong-Ze Peng, Li-Ping Liu et al. · 0 citations
Review Open access Oct 2026

From algorithm performance to clinical value in AI-assisted skin cancer diagnostics

Outcome-driven evaluation frameworks are needed to bridge the gap between algorithmic performance and meaningful healthcare impact, and future research should prioritize prospective real-world studies, outcome-driven evaluation frameworks, and economic assessments that examine the impact of AI-supported decision-making...

Lennart Ocker-Serger, E. Livingstone, G. Lodde et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.